WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Signalway Antibody
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
BioSpace | February 17, 2020
Neuropore Therapies, Inc., a biopharmaceutical company discovering and developing novel therapeutics for the treatment of neurodegenerative disorders, announced today that it has been awarded a $500,000 grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis. The grant has been made through the Association’s Lawrence and Isabel Barnett Drug Devel...
The Lynx Group | August 14, 2020
The Lynx Group (TLG) has acquired Upstream Partners in an effort to create a dynamic division catering directly to the pharmaceutical and biotech space. The ability to leverage the deep experiences and broad networks of both companies with external healthcare decision-makers and influencers together, allows the new division of TLG to provide pharmaceutical and biotech clients with thorough, market-informed perspectives needed throughout a product's life cycle. These insights are invaluable f...
MedTech
Pfizer Inc | August 24, 2021
Pfizer Inc. and Trillium Therapeutics Inc. today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash. This represents a 118% premium to the 60-day...
Cell and Gene Therapy
Mission Bio | July 18, 2022
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of solid tumor assays through its Pharma Assay Development (PAD) services. The availability of this new service offering will help to accelerate the development of cancer therapeutics by reducing the time and cost associated with the characterization of solid tumor cells. Precision therapeutics for solid tumors have been historically bottlenecked due to technical challe...
Medical
Whitepaper
Medical, Industry Outlook
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE